MBD-004

MBD-004 is a preclinical-stage gene therapy candidate being developed by Medera Biopharmaceutical for the treatment of pulmonary hypertension and pulmonary fibrosis. As part of Medera's pipeline of disease-modifying genetic therapies, MBD-004 is designed to address the underlying molecular drivers of lung remodeling and vascular dysfunction. While the specific genetic cargo and viral vector platform for MBD-004 have not been publicly disclosed, the program aims to provide long-term therapeutic benefits for patients suffering from chronic respiratory and pulmonary vascular diseases by intervening at the genetic level.